Fisher & Paykel Healthcare (ASX:FPH) Addresses Impact of New US Tariffs
Fisher & Paykel Healthcare (ASX:FPH) outlines its response to new US tariffs, detailing operational and financial strategies.
Category: Healthcare
Cochlear Limited (ASX:COH) Awaits Clarification on US Tariff
Cochlear Limited (ASX:COH) awaits clarification on new US export tariffs, expecting further details and market updates soon.
Biome Australia Limited (ASX:BIO) Reports Strong Q3 FY25 Sales Growth
Biome Australia (ASX:BIO) reports a 41% increase in Q3 FY25 sales revenue, highlighting strong growth and positive future outlook.
Mesoblast (ASX:MSB) Secures Medicaid Agreement for Ryoncil®
Mesoblast (ASX:MSB) enters Medicaid agreement with CMS for Ryoncil®, enabling treatment for children with SR-aGvHD.
Artrya Limited (ASX:AYA) Receives FDA Clearance for Salix® Coronary Anatomy
Artrya Limited (ASX:AYA) secures FDA clearance for Salix® Coronary Anatomy, facilitating its commercial launch in the US market.
Avecho Biotechnology Limited (ASX:AVE) Receives US$3M Licensing Fee from Sandoz
Avecho Biotechnology Limited (ASX:AVE) receives a US$3M upfront licensing fee from Sandoz AG for its CBD treatment for insomnia in Australia.
Healius (ASX:HLS) Announces Pathology Strategy and $300M Dividend at Investor Day 2025
Healius (ASX:HLS) reveals a new pathology strategy and a $300 million special dividend during Investor Day 2025.
Prescient Therapeutics (ASX:PTX) Initiates Phase 2a PTX-100 Clinical Study
Prescient Therapeutics (ASX:PTX) initiates Phase 2a clinical study for PTX-100, marking a significant milestone in treating Cutaneous T-Cell Lymphoma.
LTR Pharma Limited (ASX:LTP) Advances Multi-Market Strategy with FDA Milestone and Roxus Launch
LTR Pharma (ASX:LTP) achieves FDA approval path for SPONTAN and launches Roxus to accelerate US market entry.
4DMedical Limited (ASX:4DX) Announces $6.5m Annual Cost Reduction Program
4DMedical Limited (ASX:4DX) announces $6.5m annual cost reductions, supporting ongoing growth and key milestones.